- Group net sales rose 7.3% to EUR 27.8 billion in 2025; R&D spending increased to EUR 6.4 billion (22.9% of sales) and 70 million patients were reached.
- Human Pharma sales were EUR 22.7 billion (+7.4%); JARDIANCE (empagliflozin) €8.8bn and OFEV (nintedanib) €3.8bn; unit R&D €5.8bn (27.4%).
- Two launches in H2 2025: HERNEXEOS (zongertinib) launched in the US in Aug 2025 for HER2‑mutant NSCLC; JASCAYD (nerandomilast) approved in Oct 2025 in the US and China for IPF and in Dec 2025 for PPF.
- Animal Health sales were EUR 4.9 billion (+6.5%); NEXGARD €1.4bn; EU exceptional authorizations granted for poultry vaccines VAXXINACT H5 and trivalent VAXXITEK HVT+IBD+H5 to bolster avian influenza preparedness.
Financial highlights
Group net sales rose 7.3% to EUR 27.8 billion in 2025; R&D investments increased to EUR 6.4 billion (22.9% of group net sales); 70 million patients were reached, up from 66 million in 2024.
Human Pharma performance
Human Pharma sales were EUR 22.7 billion (+7.4%); JARDIANCE (empagliflozin) reached EUR 8.8 billion (+8.7%) and OFEV (nintedanib) EUR 3.8 billion (+5.4%).
New launches and pipeline
Two medicines launched in H2 2025: HERNEXEOS (zongertinib) for HER2‑mutant advanced non‑small cell lung cancer (US launch Aug 2025) and JASCAYD (nerandomilast), approved Oct 2025 in the US and China for idiopathic pulmonary fibrosis and in Dec 2025 for progressive pulmonary fibrosis; Human Pharma R&D was EUR 5.8 billion (27.4% of unit sales) and the pipeline includes over 80 projects with more than 50 new molecular entities.
Animal Health
Animal Health sales rose 6.5% to EUR 4.9 billion; NEXGARD grew 8.5% to EUR 1.4 billion; EU exceptional marketing authorizations were granted for two poultry vaccines—VAXXINACT H5 and the trivalent VAXXITEK HVT+IBD+H5—to support avian influenza preparedness.
Outlook
For 2026 the company expects continued progress across Animal Health and Human Pharma pipelines with key inflection points in cardiovascular/renal/metabolic (CRM), oncology and eye health.
